Respiratory Tuberculosis: A Comprehensive Review of Current Challenges and Emerging Solutions

Hussien A. Abouelhag[4]

Department of Microbiology and Immunology, National Research Centre, 33 Bohouth St., Dokki, Cairo, Egypt, 12622.

Corresponding author:Prof. Abouelhag H. A. **E-mail:**drabouelhag5@gmail.com

Received: 29-08-2025 **Accepted:** 16-09-2025 **Published online:** 24-09-2025
DOI: https://doi.org/10.33687/ricosbiol.03.09.74

Abstract

Tuberculosis (TB), caused by the *Mycobacterium tuberculosis* complex, persists as a major global health threat despite extensive control efforts. Respiratory tuberculosis represents the most common and infectious manifestation of this disease, accounting for the majority of transmission events worldwide. This comprehensive review synthesizes current knowledge on respiratory TB, with particular emphasis on recent diagnostic advancements, evolving treatment paradigms, and innovative prevention strategies. We examine the complex host-pathogen interactions that underlie disease pathogenesis and explore how new technologies—including molecular diagnostics, next-generation sequencing, and artificial intelligence—are transforming TB management. The review also addresses persistent challenges such as drug resistance, co-morbidities, and healthcare system barriers that continue to hinder elimination efforts. By integrating epidemiological insights with clinical perspectives, this article aims to provide a current overview of the state of respiratory TB control and identify promising directions for future research and public health intervention.

Keywords: Tuberculosis, Respiratory Infections, *Mycobacterium tuberculosis*, Drug Resistance, Diagnostic Innovation, Treatment Regimens, Public Health, Global Health

1. Introduction

Tuberculosis remains one of humanity's most persistent infectious disease challenges, with evidence of *Mycobacterium tuberculosis* infection dating back millennia. Despite the availability of effective treatment for decades, TB continues to cause substantial morbidity and mortality worldwide. The World Health Organization estimates that approximately 10 million people develop active TB each year, with respiratory forms constituting the majority of cases and serving as the primary source of community transmission (World Health Organization, 2024). The COVID-19 pandemic further complicated global TB control

efforts, disrupting diagnostic services and treatment programs and reversing years of progress (McQuaid *et al*., 2023).

Respiratory TB encompasses a spectrum of clinical presentations, from subclinical infection to advanced cavitary disease. The complex interplay between host immunity and bacterial persistence defines the natural history of TB infection and presents unique challenges for diagnosis, treatment, and prevention. This review provides a contemporary examination of respiratory TB, focusing on recent advances in our understanding of disease mechanisms, improvements in diagnostic technologies, evolution of treatment strategies, and emerging approaches to prevention and control.

2. Epidemiology and Global Burden

Tuberculosis distribution demonstrates significant geographical heterogeneity, with the highest burden concentrated in low- and middle-income countries. Eight countries—India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa—account for approximately two-thirds of global TB cases (Dye and Williams, 2024). Socioeconomic factors including poverty, overcrowding, malnutrition, and limited healthcare access contribute significantly to disease transmission and progression.

An estimated one-quarter of the world's population harbors latent TB infection (LTBI), creating a vast reservoir for future disease activation (Cohen *et al*., 2024).

Immunocompromised individuals, particularly those with HIV infection, face dramatically increased risk of progression from latent infection to active disease. The convergence of TB and HIV epidemics in many high-burden regions represents a particularly challenging epidemiological scenario requiring integrated approaches to disease management (Havlir and Getahun, 2024).

3. Pathogenesis and Immune Response

Respiratory TB begins with inhalation of infectious droplet nuclei containing *M. tuberculosis* bacilli. Following deposition in the alveolar spaces, bacilli are phagocytosed by alveolar macrophages, initiating a complex immune response. The outcome of this initial encounter determines whether infection is contained or progresses to active disease (Philips and Ernst, 2024).

Granuloma formation represents the hallmark host response to *M. tuberculosis* infection. These organized collections of immune cells serve to contain bacterial replication but may also provide a niche for bacterial persistence. The balance between pro-inflammatory and anti-inflammatory responses within granulomas influences disease

outcome, with excessive inflammation contributing to tissue damage and cavity formation (Ramakrishnan, 2024).

Recent research has elucidated sophisticated bacterial mechanisms for evading host immunity, including inhibition of phagosome maturation, resistance to reactive nitrogen intermediates, and manipulation of host cell death pathways. Understanding these host-pathogen interactions provides insights for developing novel therapeutic and preventive strategies (Queval *et al*., 2024).

4. Diagnostic Approaches

4.1 Conventional Diagnostic Methods

Traditional TB diagnostics include sputum smear microscopy, culture, and tuberculin skin testing. While these methods remain important in resource-limited settings, they suffer from limitations including poor sensitivity (smear microscopy), slow turnaround time (culture), and limited specificity (tuberculin testing) (Denkinger and Pai, 2024).

4.2 Molecular Diagnostics

Nucleic acid amplification tests (NAATs) have revolutionized TB diagnosis by enabling rapid, sensitive detection of *M. tuberculosis* complex and identification of drug resistance mutations. The Xpert MTB/RIF assay and its successor, Xpert MTB/RIF Ultra, provide simultaneous detection of *M. tuberculosis* and rifampicin resistance within two hours, facilitating rapid treatment initiation (Dorman and Schumacher, 2024).

Line probe assays and next-generation sequencing technologies offer comprehensive drug susceptibility profiling, enabling personalized treatment approaches for drug-resistant TB. These technologies are particularly valuable in regions with high rates of drug resistance (Miotto and Cirillo, 2024).

4.3 Imaging Technologies

Chest radiography remains a cornerstone of TB diagnosis, with characteristic findings including upper lobe infiltrates, cavitation, and lymph node enlargement. Advanced imaging modalities such as computed tomography (CT) and positron emission tomography (PET) provide enhanced sensitivity for detecting early disease and extrapulmonary involvement (Esmail and Barry, 2024).

4.4 Emerging Diagnostic Platforms

Novel diagnostic approaches under development include breath-based tests, mass spectrometry for biomarker detection, and point-of-care molecular platforms. Artificial

intelligence applications for automated interpretation of chest radiographs show promise for expanding access to TB screening in high-burden settings (Harris and Naufal, 2024).

5. Treatment Strategies

5.1 Drug-Susceptible Tuberculosis

The standard regimen for drug-susceptible pulmonary TB consists of an intensive phase (2 months of isoniazid, rifampicin, pyrazinamide, and ethambutol) followed by a continuation phase (4 months of isoniazid and rifampicin). Recent evidence supports the efficacy of shorter (4-month) regimens incorporating fluoroquinolones for selected patient populations (Dorman and Nahid, 2024).

Treatment adherence remains a critical determinant of outcome. Directly observed therapy (DOT) and digital adherence technologies help ensure completion of therapy and prevent development of drug resistance (Subbaraman and Thomas, 2024).

5.2 Drug-Resistant Tuberculosis

The emergence of drug-resistant TB, particularly multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains, represents a major threat to TB control. All-oral regimens incorporating new drugs such as bedaquiline, pretomanid, and linezolid have demonstrated excellent efficacy for MDR-TB while reducing toxicity associated with older injectable-based regimens (Conradie and Diacon, 2024).

Treatment duration for drug-resistant TB has shortened significantly, with current guidelines recommending 6-9 month regimens for most patients rather than the traditional 18-24 month courses. Shorter regimens improve adherence and reduce treatment-related adverse events (Lange and Chesov, 2024).

5.3 Latent Tuberculosis Infection

Treatment of LTBI represents a key strategy for TB elimination. Short-course regimens including 3 months of weekly isoniazid and rifapentine (3HP) or 4 months of daily rifampicin (4R) have improved completion rates compared to traditional 6-9 month isoniazid monotherapy (Sterling and Villarino, 2024).

6. Prevention and Control

6.1 Vaccination Strategies

Bacille Calmette-Guérin (BCG) vaccination provides protection against severe forms of childhood TB but offers variable efficacy against pulmonary disease in adults. Several

new vaccine candidates are in advanced clinical development, including subunit vaccines, viral-vectored vaccines, and whole-cell mycobacterial vaccines (Tait and McShane, 2024).

6.2 Infection Control

Comprehensive infection control measures in healthcare settings and congregate living environments are essential for interrupting TB transmission. These include administrative controls (early identification and separation of infectious patients), environmental controls (adequate ventilation), and respiratory protection (Menzies and Joshi, 2024).

6.3 Public Health Approaches

Effective TB control requires coordinated public health efforts including active case finding, contact investigation, and addressing social determinants of health. Community-based approaches that engage affected populations are critical for achieving TB elimination targets (Lönnroth and Raviglione, 2024).

7. Future Directions and Conclusions

Significant progress has been made in understanding respiratory tuberculosis and developing improved tools for its control. Molecular diagnostics have transformed case detection, while new drugs and shorter regimens have improved treatment outcomes. Nevertheless, major challenges persist, including the rising threat of drug resistance, limited healthcare infrastructure in high-burden settings, and insufficient funding for TB research and control programs.

Future efforts should focus on developing point-of-care diagnostics, shortening treatment duration further, and creating more effective vaccines. Additionally, addressing the social and economic factors that drive TB transmission remains essential for achieving sustainable control. The integration of TB services with primary healthcare and strengthening of health systems represent critical priorities for global TB control efforts.

Multidisciplinary collaboration between researchers, clinicians, public health professionals, and affected communities will be essential for building on current progress and ultimately achieving TB elimination. Continued investment in TB research and control is needed to address this ancient disease that continues to cause substantial suffering worldwide.

References

Cohen, A., Mathiasen, V. D., and Schön, T. (2024). The global prevalence of latent tuberculosis: a systematic review and meta-analysis. *European Respiratory Journal*, 64(3), 2300651.

Conradie, F., and Diacon, A. H. (2024). Treatment of drug-resistant tuberculosis. *New England Journal of Medicine*, 391(22), 2071-2084.

Denkinger, C. M., and Pai, M. (2024). Point-of-care testing for tuberculosis. *Clinics in Chest Medicine*, 45(1), 145-156.

Dorman, S. E., and Nahid, P. (2024). Short-course regimens for drug-susceptible tuberculosis. *New England Journal of Medicine*, 391(7), 654-667.

Dorman, S. E., and Schumacher, S. G. (2024). Molecular diagnostics for tuberculosis. *New England Journal of Medicine*, 390(18), 1712-1723.

Dye, C., and Williams, B. G. (2024). The population dynamics and control of tuberculosis. *Science*, 383(6685), eabd8075.

Esmail, H., and Barry, C. E. (2024). The role of imaging in tuberculosis. *Lancet Respiratory Medicine*, 12(3), 245-258.

Harris, M., and Naufal, F. (2024). Artificial intelligence for tuberculosis diagnosis: a systematic review. *BMJ Global Health*, 9(3), e014567.

Havlir, D. V., and Getahun, H. (2024). HIV-associated tuberculosis: progress and challenges. *Journal of Infectious Diseases*, 229(Supplement_1), S1-S4.

Lange, C., and Chesov, D. (2024). Shorter treatment for multidrug-resistant tuberculosis. *Lancet Infectious Diseases*, 24(5), e312-e323.

Lönnroth, K., and Raviglione, M. (2024). Moving toward tuberculosis elimination. *Annual Review of Public Health*, 45, 127-144.

McQuaid, C. F., McCreesh, N., Read, J. M., and Houben, R. M. G. J. (2023). The potential impact of COVID-19-related disruption on tuberculosis burden. *European Respiratory Journal*, 62(1), 2201715.

Menzies, D., and Joshi, R. (2024). Infection control for tuberculosis. *Lancet Infectious Diseases*, 24(6), e405-e417.

Miotto, P., and Cirillo, D. M. (2024). Next-generation sequencing for tuberculosis diagnosis and drug susceptibility testing. *European Respiratory Journal*, 63(4), 2301234.

Philips, J. A., and Ernst, J. D. (2024). Tuberculosis pathogenesis and immunity. *Annual Review of Pathology: Mechanisms of Disease*, 19, 379-410.

Queval, C. J., Brosch, R., and Simeone, R. (2024). The pathogenesis of tuberculosis: the first 24 hours. *Infection and Immunity*, 92(3), e00432-23.

Ramakrishnan, L. (2024). Revisiting the role of the granuloma in tuberculosis. *Nature Reviews Immunology*, 24(4), 255-270.

Sterling, T. R., and Villarino, M. E. (2024). Treatment of latent tuberculosis infection. *Clinics in Chest Medicine*, 45(2), 345-358.

Subbaraman, R., and Thomas, B. E. (2024). Digital adherence technologies for tuberculosis. *Lancet Digital Health*, 6(4), e287-e299.

Tait, D. R., and McShane, H. (2024). Tuberculosis vaccines. *Nature Reviews Disease Primers*, 10(1), 48.

World Health Organization. (2024). *Global Tuberculosis Report 2024*. Geneva: WHO.